Body
xCures, a healthcare data company, closed a $46 million Series B financing round on June 25, 2026, the company said in a press release. The round was led by Innovius Capital, with participation from iGrow, Spring Mountain Capital, and existing investors. It brings xCures' total funding to more than $76 million since the company's founding in 2018 and values the company at $127 million post-money, according to Crunchbase News, which first reported the deal.
The company builds what it calls a Clinical Clarity Engine: an AI system that pulls medical records from care sites across the United States and converts them into structured, source-traceable clinical data. xCures says the platform has processed more than 300 million medical records sourced from over 550,000 healthcare locations nationwide, and that its customer base includes 25 enterprise clients, among them diagnostics companies Exact Sciences, Caris Life Sciences, and Novocure, per the company's press release.
What the funding is for
xCures said the new capital will fund continued expansion of the Clinical Clarity Engine and support growth of its customer base beyond the current 25 enterprise accounts. The company reported that its annualized recurring revenue grew from roughly $3 million to $10 million in 2025, and that it is targeting more than $20 million in 2026, according to Crunchbase News.
"Healthcare has spent decades generating enormous amounts of patient data without a reliable way to make that information usable. We're changing that," said Mika Newton, CEO of xCures, in the company's press release.
Stu Posluns, a partner at lead investor Innovius Capital, said in the same release: "The promise of AI in healthcare depends on having accurate, complete, and trustworthy clinical data. xCures has built by far the most compelling platform we've seen for turning fragmented medical records into actionable clinical intelligence."
Who is affected
The round is directed at a specific bottleneck in clinical AI: most patient data sits in unstructured formats scattered across different providers' record systems, which makes it difficult for AI models or research teams to use reliably. xCures' pitch is that its platform normalizes that data before it reaches downstream users, rather than asking each health system or diagnostics company to solve the structuring problem on its own.
For the diagnostics and life sciences companies xCures already counts as customers, primarily labs and device makers working in oncology, the funding signals the vendor has runway to keep building out the platform they already depend on. For health systems and research organizations evaluating similar tools, the deal is a data point on how investors are currently pricing the clinical-data-structuring category: at more than 2.5 times where xCures was valued after its 2021 Series A round, when it raised $12.69 million led by the Boehringer Ingelheim Venture Fund, according to a 2021 xCures press release.
xCures has previously described applications of its platform in precision oncology, including a clinical decision support tool called xDECIDE that generates ranked treatment options from a patient's structured record, according to the company. This post is reporting the funding round and the company's own description of its platform. It is not reporting on the clinical performance or accuracy of xDECIDE or any other xCures tool, and no claim about clinical outcomes should be inferred beyond what the company has stated in its own materials.
What happens next
xCures has not disclosed a timeline for reaching its stated 2026 revenue target or announced new customers tied to this round. Coverage from Crunchbase News and MobiHealthNews did not report additional product launches tied to the financing. Readers tracking the clinical-data-infrastructure segment should watch for xCures' next customer or revenue disclosure, which would likely come with a future funding announcement or year-end reporting, since the company has not committed to interim updates.